Get the Stockscreener App
63.60
0.68%
0.46
Viking Therapeutics Inc stock is traded at $63.60, with a volume of 6.02M.
It is up +0.68% in the last 24 hours and down -2.14% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$63.14
Open:
$63.53
24h Volume:
6.02M
Relative Volume:
1.63
Market Cap:
$7.27B
Revenue:
-
Net Income/Loss:
$-96.75M
P/E Ratio:
-68.39
EPS:
-0.93
Net Cash Flow:
$-71.95M
1W Performance:
-13.33%
1M Performance:
-2.14%
6M Performance:
-17.41%
1Y Performance:
+502.56%
1-Day Range:
$62.50
$67.73
1-Week Range:
$62.50
$79.10
52-Week Range:
$9.34
$99.41
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Viking Therapeutics Offers An Obesity Drug for Healthy Adults - Yahoo Finance UK
Viking stock fluctuates amid manufacturing concerns with obesity pill - Clinical Trials Arena
Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by AlphaCentric Advisors LLC - MarketBeat
Is Viking Therepautics a Buy Now? - Yahoo! Voices
Vanguard Group Inc's Strategic Acquisition in Viking Therapeutics - GuruFocus.com
Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations - MSN
Why Viking Therapeutics Stock Plummeted After Soaring Today - sharewise
Viking Therapeutics soars then drops on obesity data - CNBC
Viking's oral weight-loss drug seems impressive, but manufacturing questions linger - FirstWord Pharma
Health Care Down as GLP-1 Enthusiasm Wanes -- Health Care Roundup - Marketscreener.com
Viking Therapeutics' Hot Stock Slips After Latest Obesity Drug Trial Results - MSN
Obesity Pill Data Portend Competition, Hitting Drugmaker Shares - Bloomberg
Viking Therapeutics stock falling amid results for new GLP-1 pill - Yahoo Finance
Viking stock drops 13% after jumping 9% on obesity drug data (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 8.7%Time to Sell? - MarketBeat
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data - MSN
Viking Therapeutics’ GLP-1 pill candidate shows promise in latest study - MM+M Online
Viking Therapeutics’ Early Clinical Data Continue to Build Case for Its Oral Obesity Drug - MedCity News
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial - MSN
Laidlaw maintains Buy on Viking Therapeutics, target at $110 - Investing.com
Stocks to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel - The Wall Street Journal
Viking Therapeutics Shines With Promising Results For New Obesity Drug - Finimize
Wall Street Lunch: Viking Therapeutics Thrives In Obesity Drug Saga (undefined:VKTX) - Seeking Alpha
Viking Therapeutics shares hold as Jefferies maintains Buy rating - Investing.com
Here's How I'm Trading Viking Therapeutics as the Stock Takes a Hit - TheStreet
What is Moving Viking Therapeutics Stock Today (VKTX)? - AskTraders
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations - Seeking Alpha
Viking Therapeutics stock jumps after ‘great’ trial of weight-loss drug - MSN
The Skinny on Viking Therapeutics Trial Results? Still a Little Thin - TheStreet
A new weight loss pill outperformed Novo Nordisk's version - Quartz
Viking Therapeutics reports encouraging results from weightloss tablet - Proactive Investors UK
Viking Therapeutics, Roblox, Trump Media: 3 Stocks In Focus - Yahoo Finance
Viking Therapeutics (NASDAQ:VKTX) Shares Gap Up After Analyst Upgrade - MarketBeat
VKTX Stock: Viking Therapeutics Shares Surge 5% After Promising Results for Oral Obesity Drug - SpeaksLY
Viking Therapeutics Stock Soars, Picks Up Retail Buzz On ‘Promising’ Early Results For Obesity Pill - MSN
Viking Therapeutics (NASDAQ:VKTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright reiterated coverage on Viking Therapeutics with a new price target - Quantisnow
Viking Therapeutics Slashes Huge Gains On Latest Obesity Drug Data - Investor's Business Daily
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety - Benzinga
Viking Therapeutics stock jumps after weight-loss pill shows ‘great outcome’ in trial - MSN
Stock to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel - The Wall Street Journal
Viking's oral obesity med sails ahead, posting 6.8% weight loss for highest dose in phase 1 - Fierce Biotech
Viking Thera highlights obesity candidate VK2735 - The Pharma Letter
Trending tickers: Berkshire Hathaway, Ryanair, Viking Therapeutics, Burberry - Yahoo Finance UK
Novo Nordisk share price falls after Viking Therapeutics pill update - Marketscreener.com
Viking Therapeutics’ Promising Results for Obesity Treatment - TipRanks
Viking Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 - Quantisnow
Viking Therapeutics Stock Soars on New Obesity Data. Why It Shows the Future of GLP-1 Drugs. - Barron's
Nvidia, Apple, Sherwin-Williams, DJT, Talen Energy, Viking Therapeutics, and More Movers - Barron's
Viking shares jump after positive early data on oral obesity pill; Lilly, Novo drop - Seeking Alpha
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viking Therapeutics Inc Stock (VKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Oct 28 '24 |
Sale |
76.61 |
131,687 |
10,089,164 |
149,366 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):